Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas

Ryan C. Lynch,Christina Poh,Chaitra S. Ujjani,Edus H. Warren,Stephen D. Smith,Mazyar Shadman,Karolyn Morris,Sydney Lee,Heather Rasmussen,Susan Ottemiller,Megan Shelby,Sarith Keo, Kaitlin Verni,David M. Kurtz,Ash A. Alizadeh,Jacob J. Chabon,Gregory J. Hogan, Andre Schulz,Ted Gooley,Jenna M. Voutsinas

Blood advances（2023）

引用 1|浏览13

暂无评分

摘要

•Pola-DA-EPCH-R has an acceptable safety profile that is similar to that of previously published results of the standard DA-EPOCH-R regimen.•Substituting vincristine with Pola did not appear to affect the ability to escalate chemotherapy dosing beyond dose level 1.

查看译文

关键词

polatuzumab vedotin,infusional chemotherapy,b-cell,non-hodgkin

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要